Dare Bioscience, Inc. (DARE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Dare Bioscience, Inc. is a biopharmaceutical company focused on women's health, operating in a single segment. The company recently announced a strategic shift in March 2025 to a "dual-path" approach, pursuing both traditional FDA approval and earlier market access via Section 503B compounding for select proprietary formulations. The company has no sales or marketing infrastructure and relies on third-party partners for commercialization.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $(21,172) | $22,438 | $4,255 | $31,740 |
| Net Loss | $(4,016,483) | $12,910,656 (Income) | $(8,394,790) | $6,155,300 (Income) |
| Operating Expenses | $3,806,628 | $7,381,904 | $8,413,173 | $13,413,679 |
| Cash and Cash Equivalents | $5,035,006 (as of June 30, 2025) | |||
| Working Capital Deficit | ~$12.6 million (as of June 30, 2025) | |||
| Accumulated Deficit | $183.7 million (as of June 30, 2025) | |||
| Net Cash Used in Operating Activities | $(10.9 million) YTD 2025 |
Note: Q2 2025 revenue is negative due to an adjustment for lower actual royalty revenue than previously estimated for the prior quarter. Q2 2024 net income was driven by a one-time gain of ~$20.4 million from the sale of royalty rights to XOMA.
Material Changes vs. Prior Period
- Revenue Volatility: Revenue turned negative in Q2 2025 due to a downward adjustment of estimated royalties from the XACIATO license with Organon. This contrasts with Q2 2024, which included a significant non-recurring gain from the sale of future royalty rights.
- Expense Reduction: Total operating expenses decreased by approximately 48% in Q2 2025 compared to Q2 2024. Research and Development (R&D) expenses dropped 71%, primarily due to increased "contra R&D" expenses (grant funding offsets) and reduced manufacturing costs for Ovaprene and Sildenafil Cream.
- Liquidity Position: Cash and cash equivalents declined from $15.7 million at year-end 2024 to $5.0 million at June 30, 2025. The company reported a working capital deficit of approximately $12.6 million.
- Grant Funding: The company recognized significant contra R&D expenses ($4.5 million in Q2 2025) from grants received from the Bill & Melinda Gates Foundation, NIH, and others, which offset a substantial portion of gross R&D spending.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the 12 months following the report date due to the working capital deficit and history of losses. Additional capital is required to fund operations.
- Strategic Outlook: The company expects to begin recording revenue from Section 503B compounded products (DARE to PLAY Sildenafil Cream) in Q4 2025, though revenue is not expected to be material in 2025. DARE-HRT1 is targeted for late 2026.
- Capital Raising: Subsequent to June 30, 2025, the company raised approximately $17.6 million via an ATM offering and received a $6.0 million grant payment. However, further capital raises may be necessary.
- Key Risks:
- Dependence on non-dilutive grants and government funding, which faces uncertainty due to federal policy changes and potential budget freezes.
- Reliance on third parties (Organon, Bayer, XOMA) for commercialization and milestone payments.
- Nasdaq Compliance: The company regained compliance with the Stockholders' Equity Rule in July 2025 but is subject to a one-year mandatory monitoring period.
- Regulatory delays or failures in clinical trials for key candidates like Ovaprene and Sildenafil Cream.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.0 million cash balance (largely restricted grant funds) against the $12.6 million working capital deficit and ongoing burn rate.
- Grant Sustainability: Assess the risk of federal funding cuts (NIH/NIH) and the specific terms of the Gates Foundation grants supporting DARE-LARC1 and Ovaprene.
- Revenue Recognition: Understand the volatility of royalty revenue from XACIATO, which is now largely monetized to XOMA and UiE, leaving the company with limited direct revenue streams.
- Nasdaq Status: Monitor the one-year mandatory monitoring period for Stockholders' Equity compliance starting July 24, 2025.
- Subsequent Events: Confirm the utilization of the $17.6 million raised via ATM and the $6.0 million grant received in July 2025 to mitigate immediate liquidity risks.